Innovent Biologics' (HKG:1801) attributable loss widened to 392.6 million yuan in the first half from 139.1 million yuan in the year-ago period, according to a Wednesday filing with the Hong Kong Stock Exchange.
Loss per share at the drug company widened to 0.24 yuan from 0.09 yuan in the previous year.
Revenue from contracts with customers grew to 3.95 billion yuan from 2.70 billion yuan a year earlier.
Shares closed 1% lower during Thursday's trading.
Price (HKD): $43.50, Change: $-0.60, Percent Change: -1.36%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments